ReviewAdvances in therapy2026
Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric blepharokeratoconjunctivitis (PBKC) is a chronic inflammatory condition of the ocular surface that affects the eyelids, conjunctiva, and cornea that can lead to corneal scarring and permanent vision loss if untreated. The condition presents with diverse clinical features, necessitating a broad range of therapeutic approaches. Current management strategies include eyelid hygiene practices, topical and systemic antibiotics, and anti-inflammatory agents, often in combination for optimal outcomes. Given the expanding spectrum of medical options and the emergence of new therapeutic avenues, staying current with available treatments can be challenging. This review, based on a PubMed search using the terms pediatric blepharokeratoconjunctivitis, pediatric ocular rosacea, pediatric phlyctenular disease, pediatric phlyctenular keratoconjunctivitis, and pediatric blepharokeratitis, aims to provide ophthalmologists with a comprehensive overview of the current medical strategies. Early and multimodal therapeutic strategies that target multiple facets of eyelid margin and ocular surface inflammation, coupled with timely amblyopia treatment, is required to prevent vision loss due to PBKC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.